Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices
November 4, 2016

Participant List

Shashi Amur  
Scientific Lead, Biomarker Qualification Program, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jiri Aubrecht  
Senior Director, Global Lead for Clinical and Translational Safety Biomarkers, Drug Safety R&D, Pfizer

Amanda Baker  
Research Scientist, Predictive Safety Testing Consortium, Critical Path Institute and Associate Professor of Medicine, University of Arizona

Robert Becker  
Chief Medical Officer, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Martha A. Brumfield  
President and Chief Executive Officer, Critical Path Institute

ShaAvhrée Buckman-Garner  
Director, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jennifer Burkey  
Scientific Director, Predictive Safety Testing Consortium, Critical Path Institute

Gregory Daniel  
Clinical Professor, Duke Fuqua School of Business and Deputy Director, Duke-Margolis Center for Health Policy, Duke University

Martha Donoghue  
Acting Associate Director, Division of Oncology Products 2, Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Meredith Freed  
Senior Research Assistant, Duke-Margolis Center for Health Policy, Duke University

Steven Gutman  
Strategic Advisor, Illumina, Inc.

Patrick Harrington  
Senior Clinical Virology Reviewer, Division of Antiviral Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Kylie Haskins  
Biologist, Biomarker Qualification Program, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

John A. Kadavil  
Lead Pharmacologist, Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gary J. Kellogg  
Special Advisor, Cancer Treatment and Diagnosis, National Cancer Institute

Nicholas King  
Senior Project Manager, Predictive Safety Testing Consortium, Critical Path Institute
Gabriela Lavezzari  
Research Director, Duke-Margolis Center for Health Policy, Duke University

Jean Lee  
Consultant, BioQaulQuan

Christopher Leptak  
Director, Office of New Drugs Regulatory Science Program and Co-Director, Biomarker Qualification Program, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Susan McCune  
Deputy Director, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Vasum Peiris  
Chief Pediatric Medical Officer - Pediatrics and Special Populations, Office of the Center Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Steven Piccoli  
Research Fellow, Bristol-Myers Squibb

Elizabeth Richardson  
Managing Associate, Duke-Margolis Center for Health Policy, Duke University

Afshin Safavi  
Chief Scientific Officer, BioAgilytix Labs

John-Michael Sauer  
Executive Director, Predictive Safety Testing Consortium, Critical Path Institute

Shelli Schomaker  
Principal Scientist, Pfizer

Meena Subramanyam  
Vice President - Biomarker Strategy, Global Biomarker Discovery and Development, Biogen

Sue-Jane Wang  
Associate Director and Biostatistics Lead/Coordinator and Biostatistics Office Liaison to OTS for the CDER Biomarker Qualification Program, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration